Case Reports in Dermatology,
Journal Year:
2022,
Volume and Issue:
14(1), P. 88 - 92
Published: April 21, 2022
An
increasing
number
of
checkpoint
inhibitor-induced
subacute
cutaneous
lupus
erythematosus
events
have
been
reported.
We
present
the
first
case
nivolumab-induced
discoid
in
a
patient
with
hepatocellular
carcinoma.
The
presents
violaceous
hypopigmented
plaques
on
pinna
bilaterally,
central
hyperpigmentation
posterior
neck,
and
other
face,
forearms,
hands.
For
management,
nivolumab
was
held
for
2
months,
Plaquenil
topical
steroids
were
added.
Nivolumab
resumed
no
further
progression
DLE
lesions
improvement
skin.
It
is
important
to
characterize
side
effects
effectively
manage
them.
JDDG Journal der Deutschen Dermatologischen Gesellschaft,
Journal Year:
2021,
Volume and Issue:
19(11), P. 1621 - 1643
Published: Nov. 1, 2021
Given
the
increasing
use
of
novel
targeted
therapies,
dermatologists
are
constantly
confronted
with
cutaneous
side
effects
these
agents.
A
rapid
diagnosis
and
appropriate
management
crucial
to
prevent
impairment
patients'
quality
life
interruptions
essential
cancer
treatments.
Immune
checkpoint
EGFR
inhibitors
frequently
used
therapies
for
various
malignancies
associated
a
distinct
spectrum
adverse
events.
Exanthematous
drug
eruptions
represent
particular
diagnostic
challenge
in
patients.
can
elicit
plethora
immune-related
exanthemas,
most
commonly
maculopapular,
lichenoid,
psoriasiform
eruptions.
Additionally,
autoimmune
bullous
dermatoses
exanthemas
connective
tissue
diseases
may
arise.
In
cases
severe,
atypical
or
therapy-resistant
presentations
an
extensive
dermatological
investigation
including
skin
biopsy
is
recommended.
Topical
systemic
steroids
mainstay
treatment.
Papulopustular
major
effect
inhibitor
therapy,
occurring
up
90
%
patients
within
first
two
weeks
depending
on
agent.
Besides
topical
antibiotics
steroids,
oral
tetracyclines
choice
treatment
also
be
as
prophylaxis.
Case Reports in Dermatology,
Journal Year:
2022,
Volume and Issue:
14(1), P. 88 - 92
Published: April 21, 2022
An
increasing
number
of
checkpoint
inhibitor-induced
subacute
cutaneous
lupus
erythematosus
events
have
been
reported.
We
present
the
first
case
nivolumab-induced
discoid
in
a
patient
with
hepatocellular
carcinoma.
The
presents
violaceous
hypopigmented
plaques
on
pinna
bilaterally,
central
hyperpigmentation
posterior
neck,
and
other
face,
forearms,
hands.
For
management,
nivolumab
was
held
for
2
months,
Plaquenil
topical
steroids
were
added.
Nivolumab
resumed
no
further
progression
DLE
lesions
improvement
skin.
It
is
important
to
characterize
side
effects
effectively
manage
them.
